Robyn Karnauskas analyst TRUIST

Currently out of the existing stock ratings of Robyn Karnauskas, 269 are a BUY (85.94%), 43 are a HOLD (13.74%), 1 are a SELL (0.32%).

Robyn Karnauskas

Work Performance Price Targets & Ratings Chart

Analyst Robyn Karnauskas, employed at TRUIST, carries an average stock price target met ratio of 51.76% that have a potential upside of 39.04% achieved within 274 days on average.

Robyn Karnauskas’s has documented 637 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BIIB, Biogen at 16-May-2024.

Wall Street Analyst Robyn Karnauskas

Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.

Average potential price target upside

ABBV AbbVie ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BTAI BioXcel Therapeutics DCPH Deciphera Pharmaceuticals LLC GILD Gilead Sciences IMVT Immunovant  KOD Kodiak Sciences PTCT PTC Therapeutics RCUS Arcus Biosciences REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics BMY Bristol-Myers Squibb Company DRNA Dicerna Pharmaceuticals FATE Fate Therapeutics INFI Infinity Pharmaceuticals MRK Merck mpany PFE Pfizer ASMB Assembly Biosciences NCNA NuCana PLC SRPT Sarepta Therapeutics CELG Celgene OPT Opthea Ltd ROIV Roivant Sciences Ltd TIL Instil Bio . MEIP MEI Pharma MNTA Momenta Pharmaceuticals LLY Eli Lilly and Company QURE Uniqure NV CHRS Coherus BioSciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

190

$19.53 (11.46%)

180

6 days ago

38/39 (97.44%)

$18.61 (10.86%)

495

Buy

187

$16.53 (9.70%)

195

1 months 26 days ago

10/13 (76.92%)

$27.38 (17.15%)

191

Buy

189

$18.53 (10.87%)

181

4 months 18 days ago

9/11 (81.82%)

$15.71 (9.07%)

252

Buy

195

$24.53 (14.39%)

180

4 months 18 days ago

9/10 (90%)

$21.71 (12.53%)

445

Hold

165

$-5.47 (-3.21%)

157

5 months 7 days ago

11/11 (100%)

$2.96 (1.83%)

314

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Robyn Karnauskas is most bullish on?

Potential upside of $116 has been obtained for BIIB (BIOGEN)

Which stock is Robyn Karnauskas is most reserved on?

Potential downside of -$33.88 has been obtained for LLY (ELI LILLY AND COMPANY)

What Year was the first public recommendation made by Robyn Karnauskas?

On 2011

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?